This post was originally published on this site Magrolimab, an experimental antibody developed by Forty Seven, was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The designation is given to therapies that show potential to treat serious health conditions, and…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved use of a device, called LiPlaCis DRP, that works to predict response to the next-generation investigational chemotherapy LiPlaCis in a planned Phase 3 clinical trial in people with metastatic breast cancer, Oncology Venture, the company developing both, reports. The FDA is…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Erleada (apalutamide) for the treatment of men with metastatic castration-sensitive prostate cancer (mCSPC), or those whose cancer still responds to androgen deprivation therapy (ADT). The decision is based on the double-blind TITAN Phase 3 trial (NCT02489318), as it showed…

This post was originally published on this site To raise funds and disease awareness, as well as to encourage patients, the Lymphoma Research Foundation (LRF) is presenting its annual Light it Red (LIR) for Lymphoma effort. The September-long initiative is aimed at getting buildings and landmarks bathed in red, and getting supporters to wear the color. The…

This post was originally published on this site A new imaging technique that combines ultrasound and photoacoustic imaging of the prostate delivers detailed information about the prostate’s anatomy and cancer location, identifying some cancers that would be invisible to conventional imaging. The approach, called transrectal ultrasound and photoacoustic device, or TRUSPA, may enable earlier detection…

This post was originally published on this site IMV announced that it has joined with the Wistar Institute to develop an immunotherapy targeting cancer cells with mutations in the BRAF gene. Such mutations are linked to some types of ovarian and other cancers. Under the partnership, IMV will use its proprietary DPX drug delivery platform to…

This post was originally published on this site Ygalo (melflufen) combination therapy continues to demonstrate promising results, without significant side effects, in patients with relapsed or refractory multiple myeloma, updated data from two clinical trials show. The findings were presented at the Society of Hematologic Oncology (SOHO) 2019 Annual Meeting, held Sept. 11–14 in Houston,…

This post was originally published on this site Adding the immune checkpoint inhibitor Imfinzi (durvalumab) to standard chemotherapy care significantly extends the survival of patients with untreated extensive-stage small cell lung cancer (ES-SCLC), an aggressive form of lung cancer, a Phase 3 trial shows. The trial’s findings were presented at the Presidential Symposium of the…

This post was originally published on this site The 2019 Lasker-DeBakey Clinical Medical Research Award has been granted to scientists H. Michael Shepard, PhD, Dennis J. Slamon, MD, PhD, and Axel Ullrich, PhD, for their development of the breast cancer therapy Herceptin (trastuzumab). The Lasker Awards are widely regarded as America’s most prestigious biomedical research awards and…

This post was originally published on this site In a campaign featuring World Wrestling Entertainment (WWE) superstar and leukemia survivor Roman Reigns, video game publisher 2K is partnering with the Leukemia & Lymphoma Society to heighten awareness around blood cancers. The global partnership corresponds with 2K’s release of professional wrestling video game WWE 2K20, slated…

This post was originally published on this site The European Commission has approved a combination of Keytruda (pembrolizumab) with Inlyta (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The approval is based on the results of the multi-center KEYNOTE-426 Phase 3 trial (NCT02853331), which involved 861 untreated patients with metastatic…

This post was originally published on this site The imaging agent 68Ga-PSMA-11 has better detection rates than 18F-fluciclovine in men with recurrent prostate cancer who have already had radical surgery to remove the prostate and whose levels of prostate-specific antigen (PSA, a marker of disease) are very low, a study says. The findings of the…